Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A novel adjuvant technology for use in vaccines and in antibody production that gives excellent immune responses with low manufacturing costs, and can be administered by a variety of routes More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
In order to, to achieve the most active action of body energy, it is known that pH of water-containing blood should be maintained at an alkaline of 7.35 to 7.45. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Oct 2011 - 113 pages - $2,795
May 2011 - 15 pages - $250
May 2008 - 70 pages - $1,999
Jan 2010 - $75
May 2011 - 15 pages - $250
Nov 2010 - 28 pages - $600
Oct 2009 - 30 pages - $995
May 2011 - 25 pages - $125
Oct 2010 - 25 pages - $250
May 2011 - 15 pages - $250
Your selection
Browse By
- Industry sector
- Diagnostic
- Equipment supplies
- General supplies
- Health & Hygiene
- Medical device
- Nutrition
- Petcare
- Pharmaceutical
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us